CMV Disease
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (NCT03443869) | Merck Sharp & Dohme LLC | 2018-05-03 |
| Adoptive Immunotherapy for CMV Disease (NCT00159055) | Hadassah Medical Organization | 2004-02-01 |
| Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients (NCT00225394) | University of Massachusetts, Worcester | 2003-10-01 |
| Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease (NCT03010332) | Atara Biotherapeutics |
Track CMV Disease automatically
Every clearance here is in the API, with alerts when new ones post.